Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16. Juli 2024 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13. Juni 2024 09:10 ET
|
Aeterna Zentaris Inc
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...
Aeterna Zentaris and Ceapro Complete Merger Transaction
03. Juni 2024 09:15 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two...
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
17. Mai 2024 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously...
Aeterna Zentaris Reports First Quarter 2024 Financial Results
14. Mai 2024 18:00 ET
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Aeterna Zentaris Announces Effective Date of Share Consolidation
01. Mai 2024 07:55 ET
|
Aeterna Zentaris Inc
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously...
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
15. Februar 2024 17:50 ET
|
Aeterna Zentaris Inc
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available...
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
11. Oktober 2023 08:00 ET
|
Aeterna Zentaris Inc
– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
09. August 2023 08:05 ET
|
Aeterna Zentaris Inc
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency ...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
13. Juli 2023 07:30 ET
|
Aeterna Zentaris Inc
Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position...